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Background
Cutaneous polyarteritis nodosa (c-PAN) is a necrotizing
vasculitis of small and medium-sized vessels limited to
the skin, characterized by the presence of subcutaneous
nodular, painful, non purpuric lesions with or without
livedo reticularis occurring predominantly in the lower
extremities, with no systemic involvement. The cause of
c-PAN is unknown: infectious agents in childhood and
immunodeficiency in adults have been associated with
the disease.
Aim
To our knowledge the association of c-PAN and Com-
mon Variable Immunodeficiency (CVID) has not been
reported so far.
Case report
A 2 year-5 months old girl was referred for intermittent
fever and cutaneous erythematous, painful nodular
lesions on feet, ankles and pretibial regions. A skin
biopsy showed a necrotizing non-granulomatous vasculi-
tis. Diagnosis of cutaneous polyarteritis nodosa was
made and treatment with methotrexate (MTX), predni-
sone and ibuprofen was started. One year later, due to
insufficient response, MTX was switched to azathiopr-
ine. We obtained a good clinical control in 4 months,
thus NSAIDs and steroids were progressively stopped.
At an 8 months follow-up, laboratory test were all in
the normal range, except for progressive hypogamma-
globulinemia (IgA and IgM, 29.4 mg/dl; and 28 mg/dl;
IgG= 571 mg/dl). Immunological tests showed: IgG2
deficiency (42 mg/dl) total white count at lower limits,
with lymphopenia (21.6%); lymphocyte subpopulations
showed deficiency of CD19+ B cells (3%, normal values:
6-25%) and a poor response to protein vaccines. Due to
the 1-year persistent remission on therapy, AZA was
tapered and stopped. After several months, hypogamma-
globulinemia persisted, thus excluding a potential side
effect related to AZA treatment. Six months later, due
to a disease flare, AZA was restarted in addition to pre-
dnisone (1 mg/kg/die) and IVIG every 4 weeks (2 gr/
kg). IVIG treatment was added in order to combine
their anti-inflammatory effect with the CVID replace-
ment therapy. At last follow-up her c-PAN is in clinical
remission on AZA only. IVIG treatment is still needed
for replacement (400 mg/kg monthly), due to her CVID.
Of note, during her long term (6 years) follow-up in our
Unit, she never developed any major infection.
Conclusions
c-PAN and CVID are both due to immune system dys-
regulation, with not well known mechanisms. In our
patient, immunosuppressive therapy could have induced
a B-immunodeficiency, or could have uncovered a pre-
existing immunodeficient status. However, a casual asso-
ciation or the possibility of c-PAN as onset of CVID
cannot be excluded.
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